SOURCE: Sancilio & Company

October 01, 2007 08:58 ET

Sancilio & Company, Inc. Announces First China-Based 21 CFR Part 210/211 Compliance Audit Group for Pharmaceutical Importers of Asian-Made Materials, Supplies, Products and Excipients

RIVIERA BEACH, FL--(Marketwire - October 1, 2007) - Sancilio & Company, Inc. (http://www.sancilio.com), announces the first professionally staffed and experienced 21 CFR Part 210/211 Compliance Auditing Services for drug manufacturers importing from Asia. The new service is based in Shanghai.

According to Fred D. Sancilio, PhD, CEO and Chief Scientist of Sancilio & Company, Inc., "Recent quality issues discovered in a variety of products from Asia are urging U.S. companies to increase their vigilance in quality while importing when importing materials from overseas. American pharmaceutical, nutritional and food manufacturers typically have responded by physically sending auditors from the United States to Asia. Our new facility obviates this approach, as our Chinese auditors -- fully fluent in English and Mandarin and trained in US cGMP procedures -- are already on the ground."

Dr. Sancilio added, "Offering hands-on compliance auditing experience, our China-based auditing experts provide extremely fast turnaround, at a small fraction of the present costs to U.S. companies. Direct benefits of our new 21 CFR Part 210/211 Compliance Audit Service are enhanced assurance of compliance, integrity of product, cost effective redundant review of the quality of supply, elimination of long delays at U.S. ports of entry, and drop-in audits at any time."

About Sancilio & Company, Inc.

SCI began operations as a pharmaceutical research and development company in 2006, focused on solving difficult formulation and analytical challenges. Its rapid response service provides companies with a quick solution to pressing problems using our cGMP contract services laboratory.

SCI also offers the pharmaceutical industry a broad line of intelligent solutions to their manufacturing machinery needs. Offering tablet, capsule, blending, granulating and packaging machines at affordable prices has become the focus of the company's pharmaceutical machinery business.

SCI and its team of scientists, formulators and professionals has established a boutique pharmaceutical laboratory to support high quality drug development, targeted toward both standard and high potency pharmaceutical products. The current laboratories and support facilities are located at 3874 Fiscal Court, Suite 200 in Riviera Beach, Florida 33404, tel: 561-847-2302.

Contact Information